AUD251.57
0.92% today
Australia, Apr 01, 07:10 am CET
ISIN
AU000000CSL8
Symbol
CSL
Sector
Industry

CSL Stock price

AUD251.57
-8.34 3.21% 1M
-34.34 12.01% 6M
-27.76 9.94% YTD
-32.01 11.29% 1Y
-4.16 1.63% 3Y
-37.15 12.87% 5Y
+170.32 209.63% 10Y
Australia, Closing price Tue, Apr 01 2025
+2.29 0.92%
ISIN
AU000000CSL8
Symbol
CSL
Sector
Industry

Key metrics

Market capitalization AUD120.70b
Enterprise Value AUD140.78b
P/E (TTM) P/E ratio 28.97
EV/FCF (TTM) EV/FCF 42.25
EV/Sales (TTM) EV/Sales 6.15
P/S ratio (TTM) P/S ratio 5.27
P/B ratio (TTM) P/B ratio 4.03
Dividend yield 1.59%
Last dividend (FY24) AUD3.97
Revenue growth (TTM) Revenue growth 8.00%
Revenue (TTM) Revenue AUD22.90b
EBIT (operating result TTM) EBIT AUD5.77b
Free Cash Flow (TTM) Free Cash Flow AUD3.33b
EPS (TTM) EPS AUD8.60
P/E forward 25.35
P/S forward 4.85
EV/Sales forward 5.65
Show more

Is CSL a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

CSL Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a CSL forecast:

17x Buy
89%
2x Hold
11%

Analyst Opinions

19 Analysts have issued a CSL forecast:

Buy
89%
Hold
11%

Financial data from CSL

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
22,895 22,895
8% 8%
100%
- Direct Costs 11,771 11,771
8% 8%
51%
11,124 11,124
8% 8%
49%
- Selling and Administrative Expenses 1,727 1,727
2% 2%
8%
- Research and Development Expense 2,132 2,132
7% 7%
9%
7,265 7,265
12% 12%
32%
- Depreciation and Amortization 1,493 1,493
13% 13%
7%
EBIT (Operating Income) EBIT 5,771 5,771
12% 12%
25%
Net Profit 4,162 4,162
9% 9%
18%

In millions AUD.

Don't miss a Thing! We will send you all news about CSL directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the following segments: CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment provides plasma products, gene therapies, and recombinants. The CSL Seqirus segment includes predominantly influenza related products and provides pandemic services to governments. The CSL Vidor segment focuses on the distribution of products in the therapeutic areas of iron deficiency and nephrology. The company was founded on November 2, 1961 and is headquartered in Melbourne, Australia.

Head office Australia
CEO Paul McKenzie
Employees 32,000
Founded 1961
Website www.csl.com.au

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today